BLFS · As filed with the SEC
Biolife Solutions income statement, by quarter
The statement as Biolife Solutions presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Unaudited Condensed Consolidated Statements of Operations · USD thousands, except per-share amounts
| USD thousands, except per-share amounts | Q2 2026 3 months ended Jun 30, 2026 | Q1 2026 3 months ended Mar 31, 2026 | Q4 2025† 3 months ended Dec 31, 2025 | Q3 2025 3 months ended Sep 30, 2025 |
|---|---|---|---|---|
| Revenue | 28,466 | 27,500 | 18,785† | 28,067 |
| Product revenue | — | — | — | 26,250 |
| Service revenue | — | — | — | 26 |
| Rental revenue | — | — | — | 1,791 |
| Cost of revenue | 10,179 | 10,004 | — | — |
| Gross profit | 18,287 | 17,496 | — | — |
| Operating expenses: | ||||
| Product revenue | — | — | — | 9,288 |
| Service revenue | — | — | — | 7 |
| Rental revenue | — | — | — | 851 |
| General and administrative | 10,694 | 12,208 | 10,550† | 12,074 |
| Sales and marketing | 2,782 | 2,526 | 1,993† | 2,528 |
| Research and development | 2,958 | 2,650 | (67)† | 2,709 |
| IPR&D expense | 0 | — | 0† | 0 |
| Intangible asset amortization | 157 | 85 | (1,846)† | 699 |
| Total operating expenses | 16,591 | 17,469 | (16,658)† | 28,156 |
| Operating income (loss) | 1,696 | 27 | 1,347† | (89) |
| Other income: | ||||
| Interest income, net | 994 | 1,041 | 833† | 508 |
| Other income | 63 | 180 | 1,182† | 284 |
| Change in fair value of investments | — | — | 0† | 0 |
| Total other income, net | 1,057 | 1,221 | 2,015† | 792 |
| Income (loss) before income tax (benefit) expense | 2,753 | 1,248 | 3,362† | 703 |
| Income tax (benefit) expense | (42,351) | 62 | 271† | (82) |
| Net income (loss) from continuing operations | 45,104 | 1,186 | 3,535† | 621 |
| Discontinued operations: | ||||
| Loss from discontinued operations before income tax benefit | 0 | 0 | 7,535† | 0 |
| Income tax benefit | 0 | 0 | 0† | 0 |
| Loss from discontinued operations | 0 | 0 | 7,535† | 0 |
| Net income (loss) | 45,104 | 1,186 | 11,070† | 621 |
| Net income (loss) per share - Basic: | ||||
| Continuing operations (in dollars per share) | 0.92 | 0.02 | — | 0.01 |
| Discontinued operations (in dollars per share) | 0.00 | 0.00 | — | 0.00 |
| Net income (loss) per share (in dollars per share) | 0.92 | 0.02 | — | 0.01 |
| Net income (loss) per share - Diluted: | ||||
| Continuing operations (in dollars per share) | 0.91 | 0.02 | — | 0.01 |
| Discontinued operations (in dollars per share) | 0.00 | 0.00 | — | 0.00 |
| Net income per share (in dollars per share) | 0.91 | 0.02 | — | 0.01 |
| Weighted average shares used to compute income (loss) per share: | ||||
| Basic (in shares) | 48,866,822 | 48,458,536 | — | 47,925,038 |
| Diluted (in shares) | 49,294,679 | 49,248,075 | — | 48,723,535 |
† Derived: worked out from the filings, not stated in them. A fourth quarter is the 10-K year less the nine months in the third-quarter 10-Q; a quarter of cash flows is year to date less the prior year to date.
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.